1. Brown NC, Andreazza AC, Young LT. An updated meta-analysis ofoxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1-2):61-68.
2. Guidara W, Messedi M, Naifar M, et al. Predictive value of oxidativestress biomarkers in drug free patients with schizophrenia and schizo-affective disorder. Psychiatry Res. 2020;293:113467.
3. Pizzino G, Irrera N, Cucinotta M, et al. Oxidative stress: harms andbenefits for human health. Oxid Med Cell Longev. 2017;2017:8416763.
4. Sies H. Oxidative stress: from basic research to clinical application. AmJ Med. 1991;91(3C):31S-38S.
5. Atlan N, Sepici Dinçel A, Koca C. Diabetes mellitus and oxidativestress. Turk J Biochem. 2006;31(2):51-56.
6. Bulbul F, Virit O, Alpak G, et al. Are oxidative stress markers usefulto distinguish schizoaffective disorder from schizophrenia and bipolardisorder? Acta Neuropsychiatr. 2014;26(2):120-124.
7. Şahin Ş, Aybastı Ö, Elboğa G, Altındağ A, Tamam L. Effect ofelectroconvulsive therapy on oxidative metabolism in major depressivedisorder. Cukurova Med J. 2017;42(3):513-517.
8. Chen S, Xia HS, Zhu F, et al. Association between decreasedserum albumin levels and depressive symptoms in patients withschizophrenia in a Chinese Han population: a pilot study. PsychiatryRes. 2018;270:438-442.
9. Kazgan Kılıçaslan A, Yıldız S, Kurt O, Korkmaz S. Serum uric acidlevels in schizoaffective disorder. Bosphorus Med J. 2022; 9(2):93-101.
10. Kumar AN, Aruna P, Naidu JN, Kumar R, Srivastava AK. Review ofconcepts and controversies of uric acid as antioxidant and pro-oxidant.Arch Med Rev J. 2015;24(1):19-40.
11. Jinnah HA. Lesch-Nyhan disease: from mechanism to model and backagain. Dis Model Mech. 2009;2(3-4):116-121.
12. Bartoli F, Burnstock G, Crocamo C, Carrà G. Purinergic signaling andrelated biomarkers in depression. Brain Sci. 2020;10(3):160.
13. Yao JK, Dougherty GG Jr, Reddy RD, et al. Homeostatic imbalanceof purine catabolism in first-episode neuroleptic-naïve patients withschizophrenia. PLoS One. 2010;5(3):e9508.
14. Mabrouk H, Houas I, Mechria H, et al. Oxidative stress markersin schizophrenic patients. Immuno-analyse Biolog Spécialisée.2013;28(1):51-56.
15. He Q, You Y, Yu L, et al. Uric acid levels in subjects with schizophrenia:a systematic review and meta-analysis. Psychiatry Res. 2020;292:113305.
16. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205-212.
17. Luo Q, Wen Z, Li Y, et al. Assessment causality in associations betweenserum uric acid and risk of schizophrenia: a two-sample bidirectionalmendelian randomization study. Clin Epidemiol. 2020;12:223-233.
18. Bartoli F, Crocamo C, Mazza MG, Clerici M, Carrà G. Uric acid levelsin subjects with bipolar disorder: a comparative meta-analysis. JPsychiatr Res. 2016;81:133-139.
19. Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G.Increased uric acid levels in bipolar disorder subjects during differentphases of illness. J Affect Disord. 2015;173:170-175.
20. Kesebir S, Tatlıdil Yaylacı E, Süner O, Gültekin BK. Uric acid levelsmay be a biological marker for the differentiation of unipolar andbipolar disorder: the role of affective temperament. J Affect Disord.2014;165:131-134.
21. Belinskaia DA, Voronina PA, Shmurak VI, et al. The universal soldier:enzymatic and non-enzymatic antioxidant functions of serum albumin.Antioxidants. 2020;9(10):966.
22. Zhai D, Liu Y, Ma F, et al. Effects of the first exposure of antipsychoticson serum albumin in adolescents and young adults with first-episodeschizophrenia. J Clin Psychopharmacol. 2018;38(1):103-105.
23. Huang TL. Lower serum albumin levels in patients with mooddisorders. Chang Gung Med J. 2002;25(8):509-513.
24. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasmaantioxidants in schizophrenia. Neuropsychobiol. 2004;50(1):54-56.
25. Radhakrishnan R, Kanigere M, Menon J, Calvin S, Janish A, SrinivasanK. Association between unconjugated bilirubin and schizophrenia.Psychiatry Res. 2011;189(3):480-482.